ReviewCold Spring Harbor perspectives in medicine2016
Translating the Science of Aging into Therapeutic Interventions.
Review in Cold Spring Harbor perspectives in medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- L-deprenyl extends lifespan across mammalian species: A meta-analysis of 22 longevity experiments.Ageing research reviews · 2025Pooled it
- Fasting-mimicking diet causes hepatic and blood markers changes indicating reduced biological age and disease risk.Nature communications · 2024Trial
- Influence of Nrf2 activators on subcellular skeletal muscle protein and DNA synthesis rates after 6 weeks of milk protein feeding in older adults.GeroScience · 2017Trial
- Knockdown of the fly spliceosome component Rbp1 (orthologue of SRSF1) extends lifespan.GeroScience · 2026Article
- Histological aging signatures for monitoring tissue-specific aging and disease.Nature medicine · 2026Article
- Suppression of senescent metabolism of adipose tissue by rebalancing mitochondrial homeostasis via a selective drug delivery system.Journal of nanobiotechnology · 2026Article
- An integrated anti-aging framework targeting NADRedox biology · 2026Review
- Comprehensive cross-sectional and longitudinal comparison of sixteen markers of biological aging from the Berlin Aging Study II.Communications medicine · 2026Article
- Proteomic polygenic risk scores of age-related plasma protein levels reveal a role for Metalloproteinase inhibitor 2 (TIMP2) in cognitive performance.Neurobiology of aging · 2026Article
- Viability ofmicroPublication biology · 2026Article
- Article
- The Role of IL-6 and TNF-Alpha Biomarkers in Predicting Disability Outcomes in Acute Ischemic Stroke Patients.Life (Basel, Switzerland) · 2025Article
- Exploring Senolytic and Senomorphic Properties of Medicinal Plants for Anti-Aging Therapies.International journal of molecular sciences · 2024Article
- Developing transcriptomic signatures as a biomarker of cellular senescence.Ageing research reviews · 2024Review
- Early or Late-Life Treatment With Acarbose or Rapamycin Improves Physical Performance and Affects Cardiac Structure in Aging Mice.The journals of gerontology. Series A, Biological sciences and medical sciences · 2023Article
- The Senolytic Drug Fisetin Attenuates Bone Degeneration in theJournal of osteoporosis · 2023Article
- Connections between cross-tissue and intra-tissue biomarkers of aging biology in older adults.Epigenetics communications · 2023Article
- Are Older People Really More Susceptible to SARS-CoV-2?Aging and disease · 2022Article
- Global research trends in atherosclerosis: A bibliometric and visualized study.Frontiers in cardiovascular medicine · 2022Article
- Inflammation, Oxidative Stress, Senescence in Atherosclerosis: Thioredoxine-1 as an Emerging Therapeutic Target.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Life and health span have been extended in experimental animals using drugs that are potentially translatable into humans. Considerable effort is needed beyond the usual steps in drug development to devise the models, and realistic preclinical and clinical trial strategies are required to advance these agents into clinical application. It will be important to focus on subjects who already have symptoms or are at imminent risk of developing disorders related to fundamental aging processes, to use short-term, clinically relevant outcomes, as opposed to long-term outcomes, such as health span or life span, and to validate endpoint measures so they are acceptable to regulatory agencies. Funding is a roadblock, as is shortage of investigators with combined expertise in the basic biology of aging, clinical geriatrics, and investigational new drug clinical trials. Strategies for developing a path from the bench to the bedside are reviewed for interventions that target fundamental aging mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.